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Abstract (249/250) 
Purpose  
Dutasteride is licensed for symptomatic benign prostatic hyperplasia, and has 
been associated with a lower progression rate in low-risk prostate cancer. We 
have evaluated the effect of dutasteride on prostate cancer volume as assessed 
by T2-weighted Magnetic Resonance Imaging (MRI).  
 
Materials and methods  
In this randomized, double-blind, placebo-controlled trial, men with biopsy-
proven low-intermediate risk prostate cancer (up to Gleason 3+4 and PSA up to 
15 ng/ml) who had an MR visible lesion of >/= 0.2ml on T2-weighted sequences 
were randomized to daily dutasteride 0.5mg or placebo for 6 months. Lesion 
volume was assessed at baseline, 3 and 6 months, with an image-guided biopsy 
to the lesion at study exit. The primary endpoint was percentage reduction in 
lesion volume over 6 months. This trial was registered with the European 
Clinical Trials register (EudraCT 2009-102405-18). 
 
Results  
Forty-two men were recruited between June 2010 and January 2012. In the 
dutasteride group, the average volumes at baseline and 6 months were 0.55ml 
and 0.38ml respectively, and the average percentage reduction was 36%. In the 
placebo group, the average volumes at baseline and 6 months were 0.65ml and 
0.76ml respectively, and the average percentage reduction was -12%. The 
difference in percentage reductions between groups was 48% (95% CI 27.4-
68.3%.  p< 0.0001). The most common adverse event was deterioration in 
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erectile function (25% in men randomized to dutasteride, 16% in men 
randomized to placebo).  
 
Conclusions  
Dutasteride was associated with a significant reduction in prostate cancer 
volume on T2 weighted MRI images compared to placebo.  
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Introduction  1 
Dutasteride is licensed for men with lower urinary tract symptoms (LUTS) 2 
associated with benign prostatic enlargement1. When assessed in placebo 3 
controlled prostate cancer studies, dutasteride reduced the proportion of men 4 
diagnosed with prostate cancer by 22.8% over 4 years2, and was associated 5 
with lower rates of disease progression over 3 years in men on active 6 
surveillance3. Magnetic resonance imaging (MRI) of the prostate allows 7 
assessment of prostate cancer volume over time4,5. We report the use of MRI to 8 
assess the effect of dutasteride on prostate cancer volume in men on active 9 
surveillance.  10 
 11 
 12 
  13 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MAPPED: Effect of dutasteride on prostate cancer 
 
 6 
Materials and methods 1 
This investigator led study, sponsored by University College London, was 2 
approved by the Hammersmith & Queen Charlotte’s & Chelsea Research Ethics 3 
Committee (UK)  (09/H0707/84), the Medicines & Health Regulatory Agency 4 
and registered on the European Clinical Trials register (EudraCT 2009-102405-5 
18).  6 
 7 
Primary and secondary objectives 8 
The primary objective was to evaluate the percentage reduction in tumour 9 
volume, assessed by T2-weighted MRI (T2W-MRI), following exposure to 10 
dutasteride 0.5 mg daily for six months, compared to placebo.  11 
 12 
Secondary objectives included percentage reduction in tumour volume at 3 13 
months, and on functional MR sequences, namely dynamic contrast enhanced 14 
(DCE) imaging and diffusion weighted imaging (DWI). Prostate cancer typically 15 
shows rapid wash-in and wash-out on DCE imaging due to the increased 16 
vascularity of its’ highly permeable neo-vessels. DWI of prostate cancer typically 17 
shows restricted diffusion due to disorganized tissue structure, seen as high 18 
signal (bright areas) on high b-value imaging 6. 19 
 20 
Patient population 21 
 22 
The full study protocol has been published7. Eligible men met the UK NICE 2008 23 
active surveillance criteria8 (up to Gleason 3+4 disease, PSA up to 15 ng/ml), 24 
based on biopsy within the preceeding two years. In addition, men were 25 
required to have a >0.2 ml lesion on the standard of care T2-weighted MRI.  26 
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 1 
All eligible consented men had a study specific standardized multi-parametric 3 2 
Tesla MRI.  The images were reviewed by one study radiologist (CA, AK) to 3 
assess for the presence of a T2W lesion >0.2 ml. When confirmed, the man was 4 
randomized to placebo or dutasteride 0.5mg daily for 6 months. MRI was 5 
repeated at 3 and 6 months. Each MRI scan was reported separately by each of 6 
the study radiologists, who were blinded to treatment allocation. 7 
 8 
An exit biopsy was offered to all men, with 10 standard cores and additional 9 
cores targeted to the MRI lesion using visual registration9. Men were not re-10 
biopsied for discordant histology at baseline, in order to avoid post biopsy 11 
artefact on the study MRI scans. The concordance between baseline histology, 12 
lesion on MRI and exit histology was assessed. 13 
 14 
PSA, renal and liver function and adverse events were assessed at baseline, 3 15 
and 6 months.  16 
 17 
Randomization and masking 18 
 19 
Seventeen patients were required to complete each arm to detect a 20% 20 
reduction in tumor volume, assuming a common standard deviation of 20.5%, 21 
power of 80% and 5% statistical significance. To account for failure to complete, 22 
we aimed to recruit 21 men per arm. Men were individually randomized using 23 
block randomization with varying block sizes. The statistical team at University 24 
College London (UCL) supplied UCLH pharmacy with a randomization list to 25 
allocate study medication. The patients, study doctors, radiologists and 26 
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histopathologists were blind to treatment allocation. The radiologists and 1 
histopathologists were also blind to PSA results.  2 
 3 
Outcomes and statistical analysis 4 
The primary outcome was percentage reduction in tumor volume between 5 
baseline and 6 months on T2-weighted imaging. This was calculated using 6 
(baseline volume – 6-month volume)/baseline volume 100%, where baseline 7 
volume and 6 months volume were the average of the measurements from the 8 
two raters.  This percentage reduction was compared between the dutasteride 9 
and placebo groups using a t-test, with statistical significance set at a p-value of 10 
0.05.   11 
 12 
The secondary outcomes of percentage reduction in tumor volume as measured 13 
by DCE and DWI at six months, were compared between the dutasteride and 14 
placebo groups using a t-test. Each analysis was repeated for percentage 15 
reduction in tumour volume at three months.  16 
  17 
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Results  1 
Fifty six men consented to the study after meeting eligibility criteria based on 2 
standard of care MRI, histology and blood tests. Seven men were excluded as 3 
the study PSA or renal function did not meet the eligibility criteria. Forty-nine 4 
men had a study MRI scan. Seven of these men were excluded on MRI criteria. 5 
Forty-two men were randomized between June 2010 and January 2012 6 
(CONSORT10 diagram, figure 1).  7 
 8 
Twenty-one men were randomized to each group (Table 1). One man exited the 9 
dutasteride group prior to taking any study medication as he wished to conceive 10 
a child. Another man exited the placebo group to have active treatment in 11 
response to upgrading from Gleason 3 + 3 to Gleason 3 + 4 at UCLH pathology 12 
review. The primary endpoint was derived in 20 men within each group.  13 
 14 
When the baseline scans were formally reported, it was noted that a total of 15 
11/42 randomized men had lesions which measured as less than 0.2ml on T2-16 
weighted images by one (n = 5) or both (n=6) study radiologists. All of these 17 
men had lesions volume of 0.2ml on other sequences (DCE and diffusion 18 
weighted imaging) by at least one of the radiologists. One of the men was 19 
deemed to have a visible lesion by one radiologist but not by the other. Eight 20 
men had a mean lesion volume of <0.2ml for the lesion on T2 weighted imaging.  21 
 22 
These men were included in the analysis, as they had met the original inclusion 23 
criteria (one study radiologist assessing the MRI scan as showing a 0.2ml lesion 24 
on MRI). The agreement in volume assessment between the 2 raters was 25 
formally assessed.  26 
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 1 
Primary outcome  2 
Change in total tumor volume on T2W-MRI over 6 months (Table 2)  3 
In the dutasteride group, the average volumes at baseline and 6 months were 4 
0.55ml and 0.38ml respectively, and the average percentage reduction was 5 
36%. In the placebo group, the average volumes at baseline and 6 months were 6 
0.65ml and 0.76ml respectively, and the average percentage reduction was -7 
12% 9ie 12% growth). The difference in percentage reductions between groups 8 
was 48% (95% CI 27.4  – 68.3, p <0.0001) (figure 2).  9 
 10 
Fifteen of twenty men (75%) randomized to dutasteride had a reduction in tumor 11 
volume; 5/20 (25%) had stability (defined as < 20% volume change). No man 12 
randomized to dutasteride had an increase in tumor volume. In contrast, 2 men 13 
(10%) in the placebo group had a reduction in volume, 13 (65%) were stable 14 
and 5 (25%) exhibited an increase of > 20% (figure 3).  15 
 16 
Secondary outcomes 17 
Change in tumor volume on functional imaging over 6 months (Table 2) 18 
On DCE imaging, men randomized to dutasteride had a 42.3% reduction in 19 
tumor volume at 6 months compared to 4.2% reduction in men men randomized 20 
to placebo (38% mean difference between groups, 95% CI: 16.59- 59.64, p= 21 
0.001).   22 
 23 
On diffusion weighted imaging, men randomized to dutasteride had a 33% 24 
reduction in tumor volume at 6 months compared to a 7% increase in the men 25 
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randomized to placebo, conferring a mean difference between groups of 40% 1 
(95% CI 21.31 - 59.63, p = 0.0001).   2 
 3 
Change in tumor volume over 3 months (T2-weighted imaging) 4 
At 3 months there was a 34% reduction in tumor volume in the dutasteride 5 
group compared to 0.21% in the placebo group (mean difference between 6 
groups 34%  (95% CI 21 – 47%, p = < 0.0001).  7 
 8 
Change in prostate volume  9 
The average percentage reduction in prostate volume at 6 months was 15% in 10 
the dutasteride group, compared to an increase of 3.3% in the placebo group 11 
(mean difference between groups 18.8% (95% CI 14.9 – 22.8%, p<0.0001).  12 
 13 
Agreement between raters 14 
 15 
The agreement between the raters was investigated using a Bland-Altman plot 16 
based on the percentage reduction in tumor volume calculated separately for 17 
each individual rater (supplementary figure 1).  18 
 19 
In addition, the analysis of the primary outcome was repeated for each rater 20 
separately (supplementary table 1).  One patient was deemed by one rater to 21 
have an increase in volume and the other rater to have a reduction in volume, 22 
and this had a significant effect on the results of rater 1. The table shows the 23 
analysis with and without this outlier. The results are consistent across the 24 
raters although rater 1 has recorded a larger volume reduction than rater 2. 25 
 26 
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Histological data (Supplementary table 2) 1 
All men were offered an end of study biopsy, although 12 of 40 men declined. 2 
Histological upgrading to Gleason > 4+ 3 was seen in 3/15 (20%) in the 3 
dutasteride group, and in 6/13 (46%) in the placebo group. 4 
 5 
Concordance of MRI lesions and histology (supplementary table 3)  6 
 7 
Thirty seven men of forty men had histological confirmation of the MRI lesion at 8 
baseline or exit. The remaining three men had discordant baseline histology, of 9 
whom one had a negative exit biopsy (placebo group) and two declined the exit 10 
biopsy (one placebo, one dutasteride).  11 
 12 
PSA changes (supplementary table 4) 13 
In men on placebo, the direction of change of PSA mirrored the direction of 14 
change in tumour volume. All men on dutasteride showed a PSA reduction, with 15 
no clear correlation between the change in lesion volume and PSA.  16 
 17 
Medication compliance  18 
All men were compliant with medication according to the returned tablet count at 19 
the end of each 3 month prescription period.  20 
 21 
Adverse events 22 
No serious adverse events occurred, and no subject discontinued study 23 
medication due to adverse events. Deterioration of sexual function (at least a 4 24 
point reduction in IIEF-1511) occurred in 8 of 40 men (5/20 (25%) on dutasteride 25 
and 3/19 (16%) on placebo.   26 
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Discussion 1 
Dutasteride 0.5mg daily was associated with an average reduction in prostate 2 
cancer volume of 36%, compared to an average increase of 12% in men on 3 
placebo, as assessed by T2W-MRI over six months.   4 
 5 
This volume change was associated with less histological upgrading at targeted 6 
biopsy on study exit when randomized to dutasteride than to placebo (20% 7 
versus 46%). However, the lack of targeted biopsies at baseline to match to 8 
targeted exit biopsies and the small sample size limit the ability to definitively 9 
ascribe this to the effect of dutasteride. The rate of upgrading in the placebo 10 
group was high compared to that seen in men undergoing scheduled repeat 11 
standard 10-12 core systematic biopsy on active surveillance protocols12. 12 
However, this was expected due to the use of image-guided targeting as well as 13 
standard biopsy exit, compared to standard biopsy alone at entry, in the 14 
majority13.  15 
 16 
In 3 of 40 men there was a lack of concordance between biopsy and entry 17 
histology, not resolved on targeted biopsy at exit, which may represent a false 18 
positive MRI lesion, although 2 of the men declined the exit biopsy, and so this 19 
could not be confirmed.   20 
 21 
There have been concerns that dutasteride may act selectively on low grade 22 
tumors, and may be associated with a greater likelihood of developing high-23 
grade cancers14, although radical prostatectomy data from randomized studies 24 
have not confirmed this15.  25 
 26 
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In this study, two men randomized to dutasteride had 1mm and 2mm 1 
respectively of Gleason 4 + 4 on targeted biopsy at exit, with an overall Gleason 2 
grade of 3 + 4. At entry, the first had 9mm Gleason 3 + 3 on standard transrectal 3 
biopsy, with a lesion volume of 0.97ml, which reduced to 0.64ml at 6 months. 4 
The second had 4mm 3+ 4 on targeted biopsy at entry, with a lesion volume of 5 
0.20ml, which reduced to 0.13ml at 6 months. This grade increase on targeted 6 
biopsy at exit would be compatible with the grade shift seen with a targeted 7 
biopsy approach16.  8 
 9 
Dutasteride-associated reduction in prostate cancer volume was seen at 3 10 
months, with marginal additional reduction by 6 months, with a similar timescale 11 
to prostate volume reduction in LUTS studies. We noted greater proportional 12 
reduction in tumor volume compared to whole prostate volume which suggests 13 
that prostate cancer may be more sensitive to androgen depletion than non-14 
cancerous prostate tissue.  15 
 16 
The functional MRI sequences (DCE and DWI) assess perfusion and cell 17 
density, respectively. The percentage volume reduction in functional sequences 18 
was similar to that on T2Wi, although DWI tumor volumes were lower than on 19 
other sequences.  20 
 21 
The adverse event profile was compatible with the known side effects of 22 
dutasteride, with significantly more men taking dutasteride (25% vs 16%) 23 
showing deterioration in sexual function.  24 
 25 
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The study is limited in both its sample size and duration. The 20% threshold for 1 
a reduction in tumor volume change was chosen, as it was the least change that 2 
might be considered both clinically meaningful and assessable by our 3 
independent observers.  Sufficient men were recruited to achieve a power of 4 
80% to detect a 20% volume change. A six-month interval of assessment is 5 
common in many active surveillance protocols12, and is known to show 6 
response to dutasteride in studies of men with LUTS. The fact that a study of 7 
this size and duration could meet its primary endpoint is promising for future 8 
exploratory studies of this type.  9 
 10 
Another limitation of the study relates to the external validity of the study 11 
population. The eligibility criteria consisted of the UK NICE 2008 criteria for 12 
active surveillance in men with low or intermediate risk disease (Gleason sum 7 13 
or less, PSA < 15ng/ml), clinical T2b disease). Of note, these criteria do not 14 
include any estimation of burden of disease such as the number of cores 15 
positive, maximum cancer core length or percentage cancer core involvement. 16 
In addition to the UK NICE criteria, men were required to have a lesion visible 17 
on T2W-MRI.  18 
 19 
Men with lesions seen exclusively on functional imaging were excluded.  We do 20 
not know whether radiological phenotype predicts prognosis or responsiveness, 21 
although men with no visible lesion on MRI are at lower risk of progression than 22 
men with a visible lesion17.  23 
 24 
We assessed for an imbalance of tumor size in each group which might lead to 25 
a spurious result, if larger tumors are assumed to have a greater growth rate. 26 
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Four men had tumor volumes >1 ml, 3 of whom were randomized to placebo. 1 
We repeated the analysis with these men removed and found very similar 2 
results. In addition, a formal analysis that adjusted for baseline volume was 3 
performed with little change in the outcome.  4 
Our findings may have important clinical implications.  First, if MRI reliably 5 
detects prostate cancer volume change then it could be useful for reassessment 6 
during surveillance18. Further work is needed to determine the imaging 7 
parameters (rate of change or an absolute threshold) at which transition to 8 
active treatment should be initiated, as recommended in the recent PRECISE 9 
guidelines19 10 
 11 
Second, this novel design might be useful in assessing well tolerated agents 12 
that might modify the natural history of prostate cancer (e.g. aspirin, vitamin D, 13 
and dietary modifications including cruciferous vegetables20-22). To date, large 14 
and expensive epidemiological studies of long duration 20 using repeat random 15 
biopsies in men on active surveillance 21 have been used.  Our novel study 16 
design could allow initial screening of potential agents for further study.  17 
 18 
Conclusions 19 
Dutasteride is associated with a reduction in prostate cancer volume as 20 
assessed by T2W-MRI in men with biopsy proven low or intermediate risk 21 
prostate cancer suitable for active surveillance, over a six-month period. This 22 
novel imaged based study design may be of use in assessing response to other 23 
well tolerated interventions in men on active surveillance.  24 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MAPPED: Effect of dutasteride on prostate cancer 
 
 17 
 
2499/2500 words   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MAPPED: Effect of dutasteride on prostate cancer 
 
 18 
Disclosures 
The study was investigator-led and sponsored by University College London.  
The study was supported financially by GSK who also provided supplies of both 
drug and placebo. GSK had no input into the design, conduct and analysis of 
the study. The manuscript has been reviewed by GSK but final editorial control 
rests with the principal investigator (ME), who serves as guarantor of the study.  
 
Acknowledgements 
We would like to thank the men who gave their consent to participate in this 
study.  Mark Emberton receives research support from the United Kingdom’s 
National Institute of Health Research UCLH/UCL Biomedical Research Centre. 
Mark Emberton holds Senior Investigator status with the United Kingdom's 
National Institute of Health Research.  
 
 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MAPPED: Effect of dutasteride on prostate cancer 
 
 19 
 
References 
1.  Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual 
inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign 
prostatic hyperplasia. Urology. 2002;60(3):434-4. 
2.  Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on 
the risk of prostate cancer. N Engl J Med. 2010;362(13):1192-1202. 
3.  Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate 
cancer management: the REDEEM randomised, double-blind, placebo-
controlled trial. Lancet. 2012;379:1103-1111. 
4.  Kirkham APS, Emberton M, Allen C. How good is MRI at detecting and 
characterising cancer within the prostate? Eur Urol. 2006; 50(6):1163-1174; 
discussion 1175. 
5.  Villers A, Puech P, Mouton D, et al. Dynamic contrast enhanced, pelvic 
phased array magnetic resonance imaging of localized prostate cancer for 
predicting tumor volume: correlation with radical prostatectomy findings. J Urol. 
2006;176(6):2432-2437. 
6.  Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR 
guidelines 2012. Eur Radiol. 2012;22(4):746-757. 
7.  Robertson NL, Moore CM, Ambler G, et al. MAPPED study design: A 
6month randomised controlled study to evaluate the effect of dutasteride on 
prostate cancer volume using magnetic resonance imaging. Contemp Clin 
Trials. 2012;34(1):80-89. 
8.  National Institute for Health and Clinical Excellence. Prostate cancer: 
diagnosis and treatment (February 2008). Accessed via 
http://www.nice.org.uk/nicemedia/pdf/CG58NICEGuideline. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MAPPED: Effect of dutasteride on prostate cancer 
 
 20 
9.  Moore CM, Kasivisvanathan V, Eggener S, et al. Standards of Reporting 
for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations 
From An International Working Group. Eur Urol. 2013;64(4):544-552.  
10. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of 
randomized controlled trials. The CONSORT statement. JAMA. 
1996;276(8):637-639  
11.  Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile 
Function (IIEF): A Multidimensional Scale for Assessment of Erectile 
Dysfunction. Urology. 1997;49(6):822-830. 
12.  Dall'Era MA, Cooperberg MR, Chan JM, et al. Active Surveillance for 
Early-stage Prostate Cancer: Review of the Current Literature. Cancer. 
2008;112(8):1650-1659.  
13.  Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. "Comparison of 
MR/ultrasound Fusion-guided Biopsy with Ultrasound-guided Biopsy for the 
Diagnosis of Prostate Cancer. JAMA 2015:313(4):390-397.  
14.  Andriole GL, Bostwick DG, Gomella LG, et al.  Modeling and analysis of 
Gleason score 8-10 prostate cancers in the REDUCE study. Urology. 
2014;84(2):393-399.  
15.  Iczkowski KA, Qiu J, Qian J, et al. The dual 5-alpha-reductase inhibitor 
dutasteride induces atrophic changes and decreases relative cancer volume in 
human prostate.  Urology. 2005;65(1):76-82.  
16.  Robertson NL, Hu Y, Ahmed HU, et al. Prostate Cancer Risk Inflation as 
a Consequence of Image-targeted Biopsy of the Prostate: A Computer 
Simulation Study. Eur Urol. 2014;65(3):628-634 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MAPPED: Effect of dutasteride on prostate cancer 
 
 21 
17.  Park, BH, Jeon HG, Choo SH, et al. Role of Multiparametric 3.0 Tesla 
Magnetic Resonance Imaging in Prostate Cancer Patients Eligible for Active 
Surveillance. BJU Int 2014;113(6):864-870  
18.  Graham J, Kirkbride P, Cann K, et al. Prostate cancer: a summary of 
updated NICE guidance , BMJ. 2014;348 :f7524. 
19. Moore CM, Giganti F, Albertsen P et al. Reporting MRI in men on active 
surveurveillance for prostate cancer. The PRECISE recommendations: A report 
of a European School of Oncology Task Force. Eur Urol 2016 doi: 
10.1016/j.eururo.2016.06.011 
20.  Veitonmäki T, Tammela TLJ, Auvinen A, et al. Use of Aspirin, but Not 
Other Non-steroidal Anti-inflammatory Drugs Is Associated with Decreased 
Prostate Cancer Risk at the Population Level. Eur J Cancer. 2013;49(4):938-
945.  
21. Marshall DT, Savage SJ, Garrett-Mayer E, et al., Vitamin D3 
supplementation at 4000 international units per day for one year results in a 
decrease of positive cores at repeat biopsy in subjects with low-risk prostate 
cancer under active surveillance. J Clin Endocrinol Metab. 2012;97(7):2315-
2324. 
22.  Liu B, Mao Q, Cao M, Xie L. Cruciferous vegetables intake and risk of 
prostate cancer: a meta-analysis. Int J Urol, 2012;9(2):134-141. 
  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MAPPED: Effect of dutasteride on prostate cancer 
 
 22 
List of figures 
 
1. CONSORT diagram showing patient recruitment 
2. Waterfall plot showing percentage change of tumor volume on T2-
weighted MRI at 6 months compared to baseline for dutasteride and 
placebo groups 
3. MRI comparing baseline and six month scans in a man randomized to 
dutasteride (A) and to placebo (B) 
 
List of supplementary figures 
 
S1: Bland Altman plot showing agreement between raters  
 
 
List of tables 
1. Baseline characteristics of men in each of the treatment allocation 
groups. 
2. Change in tumor volume from baseline to 6 months  
 
List of supplementary tables 
S1. Agreement between radiological raters 
S2  Histological results at exit biopsy category by treatment group 
S3: Concordance of histology and MRI findings  
S4: PSA changes in man allocated to placebo and dutasteride  
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
MAPPED: Effect of dutasteride on prostate cancer 
 
 23 
Legends for figures 
 
Figure 1 CONSORT diagram showing men in study  
Figure 2 The percentage change in total tumor volume for all 40 patients 
between baseline and six months as measured on T2-weighted imaging  
 
Figure 3A: A 68 year-old man with a lesion in the left peripheral zone (arrow). 
The lesion is seen as low signal on T2-weighted imaging at baseline (A), and to 
have reduced in size at 3 months (B) and further at 6 months (C) after 6 months 
of daily dutasteride 0.5mg.  
 
On diffusion weighted imaging, the baseline scan (D) shows high signal lesion of 
smaller volume than the T2-weighted lesion. At 3 months (E) and 6 months (F) 
this has decreased in size, although to a lesser extent than the reduction evident 
on the T2-weighted and diffusion weighted imaging. 
 
Dynamic contrast enhanced images at baseline (G) show an enhancing lesion in 
the left peripheral zone. This reduces in volume at 3 moths (H) and 6 months (I).  
 
Figure 3B: A 71 year-old man from the placebo group with a right peripheral 
zone lesion at baseline on T2-weighted imaging (A). This is stable at 3 months 
(B) and 6 months (C).  
 
The lesion is seen as high signal on diffusion weighted imaging at baseline (D), 
and stable at 3 months (E) and 6 months (F).  
 
The lesion shows enhancement on dynamic contrast enhanced images at 
baseline (G), and whilst less conspicuous at 3 months (H) these are stable at 6 
months (I ).  
 
Figure S1  
Bland Altman plot showing the relationship between the percentage reduction in 
tumor volume between raters.  
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Table 1: Baseline characteristics in each group. Continuous variables summarized as mean (sd, range) and categorical variables 
summarized as n (%). 
 
 
 Dutasteride (n = 21) Placebo (n = 21) 
Age (yrs)  63. 9 (7.3, 49.0 to 79.2) 64.2 (7.5, 39.5 to 76.0) 
Total PSA (ng/ml) 6.94 (3.0, 1.8 to 13.4) 6.01 (2.3, 1.3 to 9.7) 
Prostate volume (ml) 47.02 (20.7, 20.7 to 98.8) 52.97 (22.1, 16.7 to 104.3) 
PSA density (ng/ml/ml) 0.16 (0.06, 0.07 to 0.28) 0.12 (0.05, 0.05 to 0.23) 
Targeted transrectal biopsy 
Targeted template biopsy 
Template guided transperineal biopsy 
Transrectal biopsy 
3 (14.3) 
3 (14.3) 
5 (23.8) 
10 (47.6) 
4 (19.1) 
3 (14.3) 
2 (9.52) 
12 (57.1) 
UCL biopsy  
Biopsy at local referral center  
12 (57.1) 
9 (42.9) 
14 (66.7) 
7 (33.3) 
Maximum Gleason 3 + 3  
Maximum Gleason 3 + 4  
Total no. of cores (median, range) 
11 (52.4) 
10 (47.6) 
12 (8 to 95) 
12 (57.1) 
9 (42.9) 
14 (8 to 64) 
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Total number of positive cores 
Percentage of positive cores 
Maximum cancer core length (mm) 
4.62 (2.8, 1 to 12) 
29.5 (21.9, 2 to 75) 
5.05 (2.3, 1 to 9) 
4.95 (3.6, 1 to 12) 
29.2 (18.4, 5 to 75) 
4.57 (2.2, 1 to 9) 
Tumor volume (ml) : T2WI 
Tumor volume (ml) : DCE 
Tumor volume (ml) :DWI 
0.55 (0.49, 0.12 to 0.36) 
0.58 (0.5, 0.06 to 2.34)  
0.48 (0.6, 0.07 to 2.70) 
0.65 (0.8, 0 to 3.27) 
0.67 (0.8, 0.09 to 3.72) 
0.42 (0.3, 0 to 1.18) 
Total index tumor volume (ml) on  
   T2 weighted imaging 
    DCE 
    Diffusion 
 
0.50 (0.34, 0.12 to 1.44) 
0.52 (0.3, 0.06 to 1.41) 
0.42 (0.3, 0.07 to 1.59) 
 
0.59 (0.6, 0 to 2.21) 
0.63 (0.7, 0.09 to 3.25) 
0.37 (0.3, 0 to 1.18) 
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ACCEPTED MANUSCRIPTTable 2: Change in total tumor volume between baseline and six months on 
T2-weighted imaging, dynamic contrast enhancement and diffusion weighted 
imaging 
 Dutasteride (20) 
Mean (sd, range) 
Placebo (20) 
Mean (sd, range) 
Mean 
difference 
(95% CI) p-
value 
Total tumor volume (ml) at 
baseline (T2)  
0.55 (0.5, 
0.12 to 2.36) 
0.65 (0.8,  
0 to 3.27) 
 
Total tumor volume (ml) at 
6 months (T2) 
0.38 (0.4, 
0.02 to 1.59) 
0.76 (0.9, 
0.09 to 3.96) 
 
% change in total tumor 
volume from 0-6 months 
(T2) 
-35.73 (25.7, 
-82.61 to 13.21) 
12.15 (37.2,  
-48.48 to 119.16) 
47.88 
(27.42, 
68.34), p 
<0.0001 
Total tumor volume at 
baseline (gadolinium/DCE) 
0.58 (0.5, 
0.055 to 2.342)  
0.67 (0.8,  
0.09 to 3.72) 
 
Total tumor volume at 6 
months (gadolinium/DCE) 
0.35 (0.3, 
0.025 to 1.328) 
0.66 (0.8, 
0.045 to 3.68) 
 
% change in total tumor 
volume from 0-6 months 
(gadolinium/DCE) 
-42.32 (25.6, 
-88.37 to 3.76) 
-4.20 (38.5, 
-64.41 to 102.22) 
38.11 
(16.59, 
59.64) 
p=0.0010 
Total tumor volume at 
baseline (diffusion) 
0.48 (0.6, 
0.07 to 2.695) 
0.42(0.3,  
0 to 1.18) 
 
Total tumor volume at 6 
months (diffusion) 
0.30 (0.3, 
0.05 to 1.284) 
0.45 (0.4, 
0 to 1.165) 
 
% change in total tumor -33.46 (21.8, 7.01 (35.9, 40.47 
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(diffusion) 
-70.49 to 20.24) -24.73 to 95.49) (21.31, 
59.63)p=0.0
001 
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List of abbreviations 
 
 
DHT = dihydrotestosterone 
 
LUTS = lower urinary tract symptoms 
 
MRI = magnetic resonance imaging 
 
T2W-MRI = T2-weighted MRI 
 
DCE = dynamic contrast enhanced 
 
DWI = diffusion weighted imaging 
 
UCLH = University College London Hospital 
 
UCL = University College London 
 
BPH = benign prostatic hyperplasia 
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Supplementary table 1 : Agreement between radiological raters 
 
Analysis Subset Dutasteride 
(n = 20) 
Mean (SD) 
Placebo 
(n = 20) 
Mean (SD)  
Mean 
difference 
(95% CI) 
P-value 
Rater 1: Percentage 
reduction in total tumour 
volume from 0-6 months 
(T2) 
41.4 (29.2) 
 
-27.3 (121.9) 68.7 
11.9 to 125.4 
P = 0.019 
(as above with outlier 
omitted) 
41.4 (29.2) 
 
-0.7 (26.8) 42.0 
23.8 to 60.2 
P < 0.0001 
    
Rater 2: Percentage 
reduction in total tumour 
volume from 0-6 months 
(T2) 
24.0 (31.9) 
 
-1.3 (31.5)  
 
25.2 
(5.0 to 45.5) 
P = 0.016  
    
Both (average): Percentage 
reduction in total tumour 
volume from 0-6 months 
(T2) 
35.7 (25.7) -5.8 (27.6) 41.5 
(24.5 to 58.6) 
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Supplementary table 2: Maximum cancer core length and maximum Gleason 
score at exit 
a) Men in the dutasteride group (n=15) 
Maximum 
core length 
Maximum Gleason score 
Total 
3+3 3+4 4+3 4+4 Too small 
2 1 1 0 0 0 2 
3 0 1 1 1 0 3 
4 0 0 0 1 0 1 
5 0 1 0 0 0 1 
6 1 1 0 0 0 2 
8 0 4 0 0 0 4 
9 1 0 0 0 0 1 
10 0 1 0 0 0 1 
Total 3 9 1 2 0 15 
 
b) Men in the placebo group (n=13) 
Maximum 
core length 
Maximum Gleason score Total 
3+3 3+4 4+3 4+4 Too small  
1 0 0 1 0 1 2 
4 0 0 1 0 0 1 
5 0 1 1 0 0 2 
7 0 2 0 0 0 2 
8 0 1 2 0 0 3 
9 0 1 1 0 0 2 
11 0 1 0 0 0 1 
Total 0 6 6 0 1 13 
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Supplementary table 3: Concordance of histology and MRI findings 
 
 
Randomization 
number 
Dutasteride (D) 
or 
Placebo (P) 
Initial histology Location of lesion 
on mpMRI 
Histology at exit Concordance  
R001 P 1 mm 3+3 left anterior horn 
1 mm 3+3 left lateral mid, 
left para mid, left para base 
Right base-mid No report Not concordant at 
baseline; no exit 
histology. Post study 
biopsy showed focal 
HGPIN only.  
R002 D 4 mm 3+3 left lateral base 
5 mm 3+3 left para base 
1 mm 3+3 left para base 
3 mm 3+3 left para mid 
Left base Targeted bx – left 
base 2 mm 3+4 
Concordant at 
baseline and exit  
R003 P 1 mm 3+3 right apex Right apex Targeted bx – 
right apex 4 mm 
4+3 
Concordant at 
baseline and exit 
R004 D 9 mm, 3mm, 2mm 3+3 left 
 
Left mid and apex Targeted bx – left 
lateral mid 2 mm 
3+4 
Concordant at 
baseline and exit 
R005 D 1 mm 3+3 left para-anterior 
apex 
1 mm 3+3 right para-
anterior apex 
2 mm 3+3 right para-
anterior apex 
1 mm 3+3 left medial 
anterior apex 
Right mid-base and 
apex 
Right para-mid 1 
mm 3+4 
Right lateral mid 
3 mm 3+3 
Right apex 1 mm 
3+3 
Right lateral base 
1 mm 3+3 
Concordant at 
baseline and exit 
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 5 
1 mm 3+3 left medial 
anterior apex 
4 mm 3+3 left medial 
anterior apex 
1 mm 3+3 left lateral 
1 mm 3+3 left lateral 
1 mm 3+3 right para-
posterior base 
3 mm 3+3 left medial 
posterior apex 
1 mm 3+3 right medial 
posterior base 
R006 P 1 mm 3+3 right post medial 
apex 
3 mm 3+3 post medial 
apex 
3 mm 3+3 right posterior 
para-apex 
Right base Right para-base 
11 mm 3+4 
Right para-mid 1 
mm 4+3 
Concordant at 
baseline and exit 
R007 P 4 mm 3+4 right base pz 
5 mm 3+3 right base pz 
1 mm 3+3 right para-base 
5 mm 3+3 left mid pz 
5 mm 3+4 left apex pz 
2 mm 3+3 apex pz  
5 mm 3+3 para-apex  
Left base-mid-apex  Targeted bx – 
left 2 mm 3+4 
Concordant at 
baseline and exit 
R008 D 4mm, 4mm, 4 mm 3+3 left  
8, 6, 5, 2 mm 3+4 right  
 
Right mid 
Left mid-base  
Targeted bx – 
right lateral mid 4 
mm 3+3 
Concordant baseline 
and exit 
R009 D 8mm, 1 mm 3+3 right  Right mid Targeted bx – Concordant at 
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 right mid 4 mm 
3+4 
baseline and exit 
R010 P 2 mm 3+3 left para-anterior 
apex 
3 mm 3+3 left para-anterior 
base 
2 mm 3+3 left para-anterior 
apex 
3 mm 3+3 right para-
anterior base 
8 mm 3+3 right para-
anterior base 
3 mm 3+3 right medial-
anterior base 
4 mm 3+3 right medial-
anterior base 
6 mm 3+3 right medial-
anterior base 
1 mm 3+3 right medial-
anterior apex 
1 mm 3+3 right medial-
anterior apex 
2 mm 3+3 right medial-
anterior apex 
Left mid-base 
Right mid-base 
No tumor at 
biopsy exit 
Concordant at 
baseline; negative at 
exit. Went on to have 
focal ablation based 
on initial template 
biopsy.  
R011 P 4mm, 2mm, 1 mm 3+4 right  
 
Right mid-base Targeted bx – 
right mid-base 8 
mm 3+4 
Concordant at 
baseline and exit 
R012 P 3 mm, 3mm  3+4 right NK 
1 mm 3+3 left  
Right mid-apex Targeted bx – 
right mid-lateral 8 
Concordant at 
baseline and exit 
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 7 
mm, 6mm  3+4 
 
R013 D 1 mm, 0.5mm 3+3 right  
 
Mid-base (anterior) Targeted bx – 
anterior 2 mm 
3+4 
 
Concordant at 
baseline and exit 
R014 D 1 mm 3+3 left lateral base 
2 mm 3+3 left central 
lateral 
1 mm 3+3 right base lateral 
1 mm 3+3 right central 
lateral 
2 mm 3+3 right apex 
Right mid-base Targeted bx – 
right mid – 6mm, 
3 mm 3+4 
 
Concordant at 
baseline and exit 
R015 P 2 mm 3+3 left anterior Right mid No tumor at 
biopsy exit 
Discordant at entry; 
negative biopsy at 
exit. Remains on 
active surveillance.  
R016 D 1 mm 3+3 right lateral 
1 mm 3+3 left para-anterior 
apex 
Right apical  Targeted bx – 
right apex-mid 3 
mm 3+4 
 
Concordant at biopsy 
and exit 
R017 D 5mm,2mm,1mm, 1mm, 1 
mm 3+4 right apex 
6mm,4mm, 2 mm 3+4 right 
base 
4 mm 3+3 left apex 
3 mm 3+4 left base 
1 mm 3+3 left base 
Right mid-lateral 
Left mid-lateral 
Right mid-lateral 
– 5 mm 3+4 
Left mid-lateral – 
2 mm 3+3 
Concordant at 
baseline and exit 
R018 D 3mm, 2mm,1 mm 3+4 right  Right mid-base Targeted bx – Concordant at 
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3 mm 3+4 left  
 
lateral 
Right mid- base 
anterior 
right mid 6 mm 
3+4 
Targeted bx – 
right base ant. 3 
mm 3+3 
 
baseline and exit 
R019 D 5mm, 4mm, 3mm, 2mm, 2 
mm 3+4 right  
1 mm, 1mm 3+3 left  
 
Left mid-apex Left para-
posterior apex - 4 
mm 3+4 
Left medial 
posterior base – 
8 mm 3+4 
Concordant at 
baseline and exit 
R020 P 2 mm 3+3 right  
5mm, 3mm, 1mm, 1mm 1 
mm 3+3 left  
 
Left mid Targeted bx – left 
mid-apex 9mm, 8 
mm, 1.5mm 3+3 
 
Concordant at 
baseline and exit 
R021 P 5mm,1mm, 1 mm 3+4 left  
1 mm 3+4 right  
Left mid Targeted bx – left 
mid 8mm, 6mm, 
4mm, 4mm, 3mm 
3+4 
  
Concordant at 
baseline and exit  
R022 P 1 mm 3+3 NK 
8 mm 3+4 NK 
3 mm 3+4 right lateral base 
1 mm 3+3 left para-apex 
1 mm 3+3 left para-base 
4 mm 3+3 right para-apex 
2 mm 3+4 right para-base 
2 mm 3+3 right lateral apex 
Right base  No biopsy at exit Concordant at 
baseline ; no exit 
biopsy. No further 
biopsies.  
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 9 
R023 D 6 mm 3+4 right lateral mid 
4 mm 3+3 right para-mid 
1 mm 3+3 right para-apex 
5 mm 3+4 right mid-
peripheral zone 
Right mid-base  Targeted bx – 
right mid-base 8, 
2mm 3+4 
 
Concordant at 
baseline and exit 
R024 P 4mm,3mm,1 mm 3+3 left 
lateral base 
 
Left mid-base  No tumor at 
biopsy exit 
Concordant at 
baseline; no biopsy 
at exit 
R025 D 4 mm, 3mm  3+4 left lateral 
base 
 
Left base  Targeted bx – left 
base 2 mm 3+3 
 
Concordant at 
baseline and exit 
R026 P 2 mm 3+3 mid-apex 
6 mm 3+3 right medial 
anterior apex 
1 mm 3+3 right mid 
anterior base 
5 mm 3+3 right mid 
anterior base 
1 mm 3+3 right medial 
posterior apex 
1 mm 3+3 right medial 
posterior base 
1 mm 3+3 right 
3 mm 3+3 right 
1 mm 3+3 targeted right 
anterior horn 
1 mm 3+3 targeted right 
anterior horn 
2 mm 3+3 targeted right 
Right mid-base  No biopsy at exit Concordant at 
baseline; no biopsy 
at exit 
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anterior horn 
5 mm 3+3 targeted right 
anterior horn 
R027 D 3mm, 1 mm 3+3 right  
5mm, 4 mm 3+3 left  
 
Right base  Targeted bx – 
right base 6mm, 
5 mm 3+3 
 
Concordant at biopsy 
and exit 
R028 P 1 mm,1mm,1mm 3+3  
6mm, 3mm, 3mm, 1mm, 1 
mm 3+3 right  
 
Right mid-base  No biopsy at exit Concordant at 
baseline; no biopsy 
at exit 
R029 P 1 mm 3+3 right base 
medial 
1 mm 3+4 right lateral base 
Right mid-base  
Left mid-base  
No biopsy at exit Concordant at 
baseline; no biopsy 
at exit 
R030 D 6 mm 3+4 right lateral base 
6 mm 3+4 right mid-lateral 
base 
Right mid  Targeted bx – 
right  mid 7 mm, 
7mm  3+4 
 
Concordant at biopsy 
and exit 
R031 D 3.5 mm 3+3 right NK 
6 mm 3+3 right NK 
0.5 mm 3+3 right NK 
Left mid  No biopsy at exit Discordant at 
baseline; no biopsy 
at exit.  
R032 D 3 mm 3+3 mid anterior 
apex I 
2 mm 3+3 para-posterior 
apex I 
1 mm 3+3 para-posterior 
apex I 
1 mm 3+3 right para-
posterior apex 
Left mid  Targeted bx – left 
mid 4 mm, 3mm, 
1mm 3+4 
 
Concordant at exit 
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4 mm 3+4 I 
R033 P 1 mm 3+3 right lateral apex 
2 mm 3+3 right mid 
7 mm 3+3 right apex 
Right mid-base  
Mid apex 
Mid-base: 4 mm 
3+3 
Concordant at 
baseline and exit 
R034 D 1 mm 3+3 left para-anterior 
apex 
4 mm 3+4 mid-apex 
1 mm 3+3 left medial 
anterior apex 
1 mm 3+3 left medial 
anterior base 
1 mm 3+3 left medial 
anterior apex 
1 mm 3+3 right medial 
anterior apex 
1 mm 3+4 left lateral 
1 mm 3+4 right medial 
posterior apex 
6 mm 3+3 right targeted 
Left mid-base  No biopsy at exit Concordant at 
baseline; no biopsy 
at exit.  
 
Exited study before 
taking medication as 
wanted to conceive. 
 
 
R035 P 1 mm 3+3 left NK 
1 mm 3+3 left NK 
1 mm 3+3 right NK 
1 mm 3+3 right NK 
Right mid-apex Targeted bx – 
right posterior 5 
mm 4+3 
Targeted bx – 
right posterior 1 
mm 4+3 
 
Concordant at 
baseline and exit 
R036 P 1.5 mm 3+3 mid-base 
4 mm 3+3 right para-
posterior apex 
Right mid No biopsy at exit Concordant at 
baseline. Exited 
study before taking 
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5 mm 3+3 right para-
posterior base 
5 mm 3+3 right para-
posterior base 
1 mm 3+3 right para-
posterior base 
12 mm 3+3 right medial-
posterior apex 
3 mm 3+3 right medial-
posterior base 
1 mm 3+3 right apex 
4 mm 3+3 right apex 
6 mm 3+3 right apex 
study medication o 
have radical 
prostatectomy due to 
upgrade of external 
histology on UCLH 
pathology. Radical 
prostatectomy 
showed Gleason 3 + 
4 (maximal 4 + 3).  
R037 P 4mm, 3mm, 3mm, 2 mm 
3+4 right 
Right mid  
Left mid  
Targeted bx – left 
5 mm 3+4 
Targeted bx –
right 4 mm 3+4 
Concordant at 
baseline and exit 
R038 P 8mm, 1 mm 3+4 right 
anterior 
3 mm 3+3 right medial 
Right mid-apex Targeted bx – 
right anterior 
9mm, 7mm, 3.5 
mm 3+4 
 
Concordant at 
baseline and exit 
R039 D 3 mm 3+3 left lateral 
8 mm 3+3 right lateral 
5 mm 3+3 right lateral 
4 mm 3+3 right lateral 
1 mm 3+3 left medial 
posterior apex 
Right mid  No biopsy at exit Concordant at 
baseline, no biopsy 
at exit 
R040 D 2 mm 3+3 right para- Right mid-base No biopsy at exit Concordant at 
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anterior apex 
1 mm 3+3 right mid-
anterior apex 
6 mm 3+3 right medial 
posterior apex 
3 mm 3+3 right medial 
posterior base 
3 mm 3+4 right peripheral 
zone 
baseline, no biopsy 
at exit 
R041 D 0.3 mm 3+3 left posterior 
3 mm 3+3 left posterior 
3 mm 3+3 left posterior 
3 mm 3+3 left mid 
1 mm 3+3 left mid 
1 mm 3+3 left anterior 
0.3 mm 3+3 left anterior 
Left mid No biopsy at exit Concordant at 
baseline, no biopsy 
at exit 
R042 P 1 mm 3+3 right lateral base 
3 mm 3+4 right lateral mid 
5 mm 3+3 right para mid 
2 mm 3+3 right para apex 
1 mm 3+3 left lateral mid 
4 mm 3+4 left lateral apex 
3 mm 3+4 left para mid 
4 mm 3+4 left para apex 
4 mm 3+4 left apex 
Left apex Left apex – 1 mm 
3+3 
Concordant at 
baseline and exit 
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Supplementary table 4 : PSA changes in man allocated to placebo and 
dutasteride 
 
 
Treatment Number of 
men in group 
Change in Lesion 
Volume 
Median change in 
absolute PSA at 6 
months 
Placebo 2  Significant 
reduction (≥ 20%) 
- 0.72 
Placebo 12  Stable lesion (20% 
reduction to 
increase of 20%) 
+ 0.75 
Placebo 6  Significant increase 
(> 20%) 
+ 1.07 
Dutasteride 15 Significant 
reduction (≥ 20%) 
- 2.3 
Dutasteride 5  Stable lesion (20% 
reduction to 
increase of 20%) 
- 3.35 
Dutasteride  0 Significant increase 
(> 20%) 
n/a 
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